ExodusPoint Capital Management’s Palvella Therapeutics PVLA Stock Holding History

ExodusPoint Capital Management’s Portfolio PVLA Stock Details PVLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.53M	Buy	+20,277	New	+$2.12M	0.02%	679
2022 Q2	–	Sell	-607	Closed	-$147K	–	2548
2022 Q1	$147K	Buy	607 +465	+327%	+$122K	﹤0.01%	1962
2021 Q4	$43K	Buy	+142	New	+$45.5K	﹤0.01%	2049
2021 Q3	–	Sell	-169	Closed	-$52K	–	2743
2021 Q2	$52K	Buy	+169	New	+$37.1K	﹤0.01%	2219

Other funds holding PVLA

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

ExodusPoint Capital Management's PVLA Position: Q1 2026 in Review

ExodusPoint Capital Management opened a new position in Palvella Therapeutics (PVLA) in Q1 2026: 20,277 shares worth $2.53M. The stake represents 0.02% of the portfolio and ranks #679 among its holdings. This is a return to the name: ExodusPoint Capital Management previously reported a position in PVLA as recently as Q1 2022.

ExodusPoint Capital Management first reported a position in PVLA in Q2 2021 and has held it in 4 quarters since. 180 funds tracked by Wall St. Rank hold PVLA as of Q1 2026.

ExodusPoint Capital Management held 20,277 shares of Palvella Therapeutics worth $2.53M as of Q1 2026.
Palvella Therapeutics was a new ExodusPoint Capital Management position in Q1 2026.
Palvella Therapeutics made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #679 holding.
ExodusPoint Capital Management first reported a position in Palvella Therapeutics in Q2 2021 and has held it in 4 quarters since.
180 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.